OPEN END TURBO SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 11:21:41 28/06/2024 pm IST | After market 12:51:42 am | |||
| 0.76 EUR | -3.80% |
|
0.795 | +4.61% |
| Current month | -5.95% | ||
| 1 month | +2.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.76 | -3.80% |
| 27/24/27 | 0.79 | +11.27% |
| 26/24/26 | 0.71 | -2.74% |
| 25/24/25 | 0.73 | 0.00% |
| 24/24/24 | 0.73 | -5.19% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 11:21 pm IST
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | MG3BQU |
| ISIN | DE000MG3BQU3 |
| Date issued | 30/04/2024 |
| Strike | 50.07 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.49 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.9 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.01 € |
| Spread % | 1.23% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51
USD
Average target price
53.19
USD
Spread / Average Target
+28.15%
- Stock Market
- Certificates
- Certificat
